新規免疫抑制剤タクロリムス水和物の発見と開発
スポンサーリンク
概要
- 論文の詳細を見る
Tacrolimus hydrate (FK506), a novel 23-membered macrolide, is an immunosuppressant isolated from Streptomyces tsukubaensis using extensive screening of fermentation products to identify a compound inhibiting the mixed lymphocyte reaction (MLR). The in vitro and in vivo immunosuppressive activities of FK506 were found to be more potent than those of cyclosporine (CyA). The superior immunosuppression with FK506 treatment was also confirmed in the skin allograft model in rats and liver transplantation in dogs. Clinical studies were initiated by Prof. Starzl at the University of Pittsburgh in 1989,and he demonstrated that FK506 surpassed CyA in the incidence of graft survival and the frequency of graft rejection. Multicenter randomized clinical studies, comparing FK506 to CyA corroborated the efficacy of FK506 on the survival of patients and of grafts, and especially on the appearance of severe refractory graft rejection. FK506 was marketed in 1993 in Japan, and was followed in 1994 in the U.S.A., U.K, and Germany. The mechanism of action of this compound was clarified by the endeavors of Prof. Schreiber, who demonstrated the existence of a binding protein for FK506 called FKBP, similar to cyclophilin for CyA. The FK506/FKBP complex binds with calcineurin, a serine/threonine phosphatase to inhibit the translocation of NFAT into the nucleus, resulting in inhibition of transcription of IL-2 mRNA. FK506 displays potent immunosuppressant activity, and contributes not only to the progress of transplantation therapy for clinical studies, but also to the clarification of signal transduction in T cell activation for basic science.
- 公益社団法人日本薬学会の論文
- 1997-08-25
著者
-
畑中 洋
藤沢薬工・探索研
-
黒田 昭雄
藤沢薬工・探索研
-
田中 洋和
藤沢薬品工業(株)筑波研究所
-
中原 邦夫
藤沢薬品工業株式会社
-
畑中 洋
藤沢薬品工業(株)
-
稲村 典昭
藤沢薬品工業(株)
-
黒田 昭雄
藤沢薬品工業(株)
-
畑中 洋
藤沢薬品工業 探究研
-
田中 洋和
藤沢薬品工業(株)
関連論文
- 13 放線菌の生産する新規免疫抑制物質FR900506の構造研究
- 日米合同薬学大会開催へ
- Micafunginの高用量での薬物動態試験
- Micafunginの高齢者における薬物動態
- Micafunginの第I相試験
- 新規免疫抑制剤タクロリムス水和物の発見と開発
- 免疫抑制剤FK-506
- 免疫抑制剤FK506(プログラフ)の臨床応用
- 移植における主要組織適合遺伝子複合体の役割とその制御 (移植を考える)